PROFESSIONAL

ACTDrug® +  

Target Cancer Genomic Profiling Service

 

ACTDrug® +: Select Drugs for Your Cancer Patient

Providing tailored drug options through precise genomic profiling for important druggable genes

A Precise Choice for Cancer Genomic Profiling

ACTDrug® +is a next-generation sequencing based assay, sequencing 40 druggable genes and 13 fusion genes & more than 350 fusion transcripts simultaneously from cancer specimens in our CAP accredited lab. This assay is specially designed for patients with breast cancer, lung, colorectal or gastric cancer, providing tailored genomic profile and recommendations of targeted drugs approved by U.S. FDA.

Exploring Various Genetic Alterations for More Precise Therapeutic Implications

ACTDrug® + performs various genetic variation analysis. Besides single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides copy number variation (CNV) analysis for 22 genes, and fusion gene detection for more precise implications.



ACTDrug® +

Hallmark of ACTDrug® +

  1. For All Solid Tumors

    Select suitable treatment for newly diagnosed patients based on druggable genetic mutations
  2. Precise Report Content

    Targeted therapy and hormonal therapy approved by U.S. FDA or in clinical trials



Why ACTDrug® +

Can be performed Fast and Accurately

  1. Drug Targeted-Based Panel

    Sequencing 40 druggable genes and 13 fusion genes & more than 350 fusion transcripts with genetic alterations
  2. Offering Tailored Drug Options

    Analyzing single nucleotide variation (SNV), small insertion/deletion (InDel), copy number variation (CNV) and fusion gene to provide tailored drug options
  3. Short Turnaround Time

    Providing professional solutions within 8-10 working days. (starting from the day qualified specimen is received at lab)
  4. High Sensitivity

    Using NGS platform for microscale specimens
  5. Pioneering Bioinformatics

    Specializing in cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science,and pharmaceutical biology to provide insightful interpretation

Specification


Next Generation Sequencing-ACTDrug®

40 druggable  genes ( TAT : 8 working days)

Next Generation Sequencing-ACTFusion

Comprehensive testing of 13 fusion genes & more than 350 fusion transcripts ( TAT : 10 working days)

Sequencing Mean Depth

>800 X


Hotspots

>3800 

Sample Types

FFPE

.5-20 unstained sections (5 µm/slide)

.1H&E stained slide (5µm)


*Cell block from pleural effusion, ascites or pericardial hydrops (≥1X106cells)




*Pleural effusion, ascties or pericardial hydrops  need to be processed into cell blocks before sending to ACT Genomics.